DeepMed Research

Xiyuan Hospital, China Academy of Chinese Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol

Phase 3

Not yet recruiting

Conditions: Acute Coronary Syndrome

Interventions: Drug: Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)
Drug: placebo capsule

First Posted Date: 2025-02-25

Last Posted Date: 2025-02-25

Lead Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 400

Registration Number: NCT06845254

Locations: 🇨🇳
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China

Study on the Effectiveness and Mechanism of Tong-Xie-Yao-Fang in Treating Diarrhea-predominant Irritable Bowel Syndrome

Phase 1

Recruiting

Conditions: Diarrhea-predominant Irritable Bowel Syndrome

Interventions: Drug: Tong-Xie-Yao-Fang

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-17

Lead Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 60

Registration Number: NCT06737666

Locations: 🇨🇳
Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China

Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome

Phase 1

Not yet recruiting

Conditions: Acute Coronary Syndrome

Interventions: Drug: Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)

First Posted Date: 2024-09-30

Last Posted Date: 2024-09-30

Lead Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 50

Registration Number: NCT06618495

Locations: 🇨🇳
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China, Beijing, Beijing, China

Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne

Phase 2

Recruiting

Conditions: Acne
Photodynamic Therapy

Interventions: Drug: N-chlorin e6 triglumine
Procedure: acne removal surgery

First Posted Date: 2024-03-15

Last Posted Date: 2024-03-15

Lead Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 46

Registration Number: NCT06311890

Locations: 🇨🇳
Xiyuan Hospital of China Academy of Chinese Medical Sciences Organization, Beijing, China

Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

Phase 4

Recruiting

Conditions: Hypertension,Essential

Interventions: Drug: Songling Xuemaikang Capsules
Behavioral: Lifestyle intervention
Drug: Placebo

First Posted Date: 2023-10-23

Last Posted Date: 2024-08-20

Lead Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 100

Registration Number: NCT06093932

Locations: 🇨🇳
China Academy of Chinese Medical Sciences Xiyuan Hospital Shanxi Hospital, Taiyuan, Shanxi, China
🇨🇳
Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China
🇨🇳
Suzhou Hosptial of Traditional Chinese Medicine, Suzhou, Jiangsu, China

and more 2 locations

Efficacy and Safety of Linggui Yangyuan Paste in Patients With Male Infertility

Early Phase 1

Not yet recruiting

Conditions: Male Infertility
Asthenozoospermia
Oligoasthenozoospermia

Interventions: Drug: LGYY mimetic
Drug: LGYY
Drug: WZYZ
Drug: WZYZ mimetic

First Posted Date: 2023-03-31

Last Posted Date: 2023-04-27

Lead Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 162

Registration Number: NCT05792813

An Early Warning Model for Assessing the Onset, Progression and Sequelae of COVID-19

Recruiting

Conditions: COVID-19

Interventions: Other: Observe and record

First Posted Date: 2023-03-09

Last Posted Date: 2023-03-09

Lead Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 378

Registration Number: NCT05761652

Locations: 🇨🇳
Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijin, China

COVID-19 Huashi Baidu Formula Clinical Study

Not Applicable

Recruiting

Conditions: COVID-19

Interventions: Drug: Huashi Baidu Granule
Drug: Monapiravir

First Posted Date: 2022-12-06

Last Posted Date: 2023-05-16

Lead Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 300

Registration Number: NCT05638672

Locations: 🇨🇳
Beijing You'an Hospital, Capital Medical University, Beijing, Beijing, China

Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D

Early Phase 1

Conditions: Non-erosive Reflux Disease
Diarrhea-Predominant Irritable Bowel Syndrome

Interventions: Drug: WPQW granule simulant
Drug: WPQW granule

First Posted Date: 2022-05-11

Last Posted Date: 2022-05-11

Lead Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 216

Registration Number: NCT05369884

Locations: 🇨🇳
Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China

Assessment on Effects of Tongjiang Granule in Treating Nonerosive Reflux Disease Overlapping Epigastric Pain Syndrome

Phase 1

Recruiting

Conditions: Gastroesophageal Reflux
Functional Dysphonia

Interventions: Drug: Tongjiang granule
Drug: Tongjiang granule simulant

First Posted Date: 2022-04-05

Last Posted Date: 2022-04-05

Lead Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 228

Registration Number: NCT05312463

Locations: 🇨🇳
Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy